Cancer Council Victoria | Victorian Cancer Trials Link

A Phase 3b Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or an Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

Clinical summary

Patients eligible to participate in this trial will receive either specified doses of Nivolumab alone, Nivolumab in combination with Ipilimumab or a chemotherapy which will be chosen by the Investigator.

Conditions

This trial is treating patients with metastatic colorectal cancer

Trial Acronym
Checkmate 8HW

Trial Identifiers
NCT04008030
CA209-8HW 2018-000040-26

Cancer
Colorectum

Age: 18+
Phase: III

For full trial details, visit trials.cancervic.org.au/details/vctl_nct04008030